Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06872892 · ClinicalTrials.gov registry record · Phase 3

The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis

A Phase 3 study of Bronchiectasis, sponsored by Boehringer Ingelheim.

Recruiting
Registry status
Phase 3
Development phase
1,755
Enrollment target
20
Study locations

NCT06872892 is a Phase 3 study of Bronchiectasis that is actively recruiting participants, run by Boehringer Ingelheim. The registered enrollment target is 1,755 participants, above the 253-participant average among 13 other Bronchiectasis trials with a reported enrollment target (594% higher). The trial reports 20 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06872892, a Phase 3 study of Bronchiectasis, is actively recruiting participants, sponsored by Boehringer Ingelheim.

RECRUITING
Registry status
Phase 3
Development phase
1,755 participants
Enrollment target
20
Study locations

Study Summary

This study is open to adults and adolescents aged 12 to under 18 with bronchiectasis. People can participate in this study if they produce sputum and have had flare-ups (also called exacerbations). The purpose of this study is to find out whether a medicine called BI 1291583 helps people with bronchiectasis. Participants are put into 2 groups randomly, which means by chance. One group takes BI 1291583 tablets and the other group takes placebo tablets. A placebo tablet looks like the BI 1291583 tablet but does not contain any medicine. Participants take 1 tablet once a day for up to 1 year and 6 months. Participants are in the study for up to 1 year and 8 months. During this time, participants visit the study site up to 10 times and get about 13 phone calls from the site staff. Participants regularly complete a diary on a smartphone about their bronchiectasis symptoms and study doctors regularly check for any changes. The study doctors document when participants experience flare-ups. The number of flare-ups is compared between the participants who receive BI 1291583 and those who receive the placebo. The study doctors also regularly check participants' health and take note of any unwanted effects.

Conditions Studied

Bronchiectasis

Interventions

  • DRUG BI 1291583
  • DRUG Placebo matching BI 1291583

Study Locations (20)

Florida

  • Central Florida Pulmonary Group - Altamonte Springs
  • Meris Clinical Research-Brandon-69466 - Brandon
  • St. Francis Medical Institute - Clearwater
  • North Florida/South Georgia Veterans Health System - Gainesville
  • University of Florida College of Medicine - Jacksonville
  • Mayo Clinic - Florida - Jacksonville
  • University of Miami - Miami
  • Essence MD Research - Naples

California

  • Newport Native MD, Inc - Newport Beach
  • Paradigm Clinical Research - Redding - Redding
  • University of California Davis - Sacramento
  • University of California San Francisco - San Francisco
  • Ventura County Medical Center - Ventura

Arizona

  • Dignity Health, St. Joseph's Hospital and Medical Center - Phoenix
  • University of Arizona - Tucson

Alabama

  • University of Alabama at Birmingham - Birmingham

Alaska

  • Providence Medical Group Alaska - Anchorage

Colorado

  • National Jewish Health - Denver

Connecticut

  • Yale University School of Medicine - North Haven

District of Columbia

  • Georgetown University - Washington D.C.

Trial Details

FieldValue
Enrollment Target 1,755 participants
Start Date 2025-06-09
Est. Completion 2028-10-12
Phase Phase 3

Sponsor

Boehringer Ingelheim

515 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06872892

The ClinicalTrials.gov registry entry for NCT06872892 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 1,755 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 253-participant average among 13 other Bronchiectasis trials with a reported enrollment target (594% higher). The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Bronchiectasis appearing as the primary indexed condition, and to 2 interventions - of which BI 1291583 is the first listed.

NCT06872892 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Florida, California, Arizona.

Frequently Asked Questions

What is clinical trial NCT06872892 about?

NCT06872892 is a clinical study titled "The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis". This study is open to adults and adolescents aged 12 to under 18 with bronchiectasis. People can participate in this study if they produce sputum and have had flare-ups (also called exacerbations). The purpose of this study is to find out whether a medicine called BI 1291583 helps people with bronc...

What is the current status of trial NCT06872892?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,755 participants. The study started on 2025-06-09. Estimated completion is 2028-10-12.

What conditions does trial NCT06872892 study?

This clinical trial studies the following conditions: Bronchiectasis.

What interventions are being tested in trial NCT06872892?

The interventions under investigation include: BI 1291583 (DRUG), Placebo matching BI 1291583 (DRUG).

Who is sponsoring clinical trial NCT06872892?

This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06872892 being conducted?

This trial has 20 study locations across Alabama, Alaska, Arizona, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Bronchiectasis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Bronchiectasis

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.